Here are the S-3 shelf registrations from LeonaBio, Inc. (LONA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow LONA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LONA filings page.
LeonaBio, Inc. has filed a resale registration statement covering up to 5,502,402 shares of common stock that may be sold from time to time by Sermonix Pharmaceuticals and its permitted transferees. These shares are issuable upon exercise of a pre-funded warrant that Sermonix received in connection with a December 2025 license agreement granting LeonaBio exclusive rights to develop and commercialize lasofoxifene in certain territories.
LeonaBio will not receive any proceeds from Sermonix’s resale of the registered shares, but would receive up to approximately $5,502 in gross proceeds if the warrant is fully exercised for cash at an exercise price of $0.001 per share, which it plans to use for working capital and to advance lasofoxifene and other pipeline drug candidates. As of December 31, 2025, 9,335,913 shares of common stock were outstanding, separate from the shares covered by this resale registration.
LeonaBio, Inc. has filed a resale registration covering up to 58,464,567 shares of common stock for potential sale by existing selling stockholders. These shares include stock already issued and shares issuable upon exercise of pre-funded warrants and common warrants that were originally sold in a December 2025 private placement. LeonaBio will not receive proceeds from any resale of shares by these holders, but could receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share and approximately $146,249,987 from cash exercise of 23,031,494 common warrants at $6.35 per share. The company plans to use any such warrant exercise proceeds for working capital and to advance its drug pipeline, including lead candidates lasofoxifene and ATH-1105. Its common stock trades on Nasdaq under the symbol “LONA.”